| Bioactivity | Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer[1]. |
| Invitro | Olinvacimab (0-1000 nM) 抑制 VEGF 与其受体 KDR 的结合，Kd 值为 0.23 nM[1]。Olinvacimab 抑制 VEGF-165，VEGF-C 和 VEGF-D 与 VEGFR-2 的结合，IC50 分别为 8.7，6.3 和 7.0 nM[1]。Olinvacimab (0.5-30 μg/mL；30 min) 抑制 VEGFR-2/KDR 和 ERK 的磷酸化[1]。Olinvacimab (1，15，20 mg/mL；30 min) 抑制 VEGF 诱导的人脐静脉内皮细胞增殖[1]。Olinvacimab (20 mg/mL；30 min) 抑制 VEGF 刺激的人脐静脉内皮细胞迁移[1]。Olinvacimab (5，10，20 μg；20 h) 剂量依赖性的抑制血管形成并干扰管状结构[1]。Olinvacimab (1 和 20 μg；6 d) 抑制 hVEGF165 诱导的大鼠主动脉环血管发芽[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | Olinvacimab (100 ng；皮下注射，1 次) 抑制体内血管生成[1]。 Animal Model: |
| Name | Olinvacimab |
| CAS | 2095504-49-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lee WS, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. MAbs. 2015;7(5):957-68. |